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The vascular hypothesis of Alzheimer’s disease (VHAD) has proposed the involvement of brain 
hypoperfusion in AD pathogenesis, where cognitive decline and dysfunction result from 
dwindling cerebral blood flow (CBF). Based on the VHAD, we focused on exploring how genetic 
factors influence AD pathogenesis via the cerebrovascular system. To investigate the role of 
CBF endophenotypes in AD pathogenesis, we performed a targeted genetic analysis of 258 
subjects from the ADNI cohort to examine associations between 4,033 SNPs of 24 AD genes 
and CBF measures in four brain regions. A novel association with CBF measure in the left 
angular gyrus (L-AG) was identified in an INPP5D SNP (i.e., rs61068452; P = 1.48E-7; 
corrected P = 2.39E-3). The gene-based analysis discovered both INPP5D and CD2AP 
associated with the L-AG CBF. Further analyses on non-overlapping samples revealed that 
rs61068452-G was associated with lower CSF t-tau/Aβ1-42 ratio. Our findings suggest a 
protective role of rs61068452-G in an AD-relevant cerebrovascular endophenotype, which has 
the potential to provide novel insights for better mechanistic understanding of AD.  
 














Alzheimer’s disease (AD) is a complex degenerative disease of the brain, characterized by 
neurodegeneration, memory impairment and cognitive problems (Jack et al., 2010). As the 
leading cause of dementia, AD is influenced by environmental and genetic factors. It is critical to 
improve the understanding of molecular mechanisms of AD because of its high prevalence, 
burdens, and currently no cure. Genome-wide association studies (GWAS) of quantitative 
endophenotypes have successfully identified a number of loci susceptible for AD (Saykin et al., 
2015), however, the underlying molecular mechanisms of how these genetic factors modulate 
AD or its biomarkers are not well characterized.  
The vascular hypothesis of Alzheimer’s disease (VHAD) (de la Torre, 2018) has 
proposed the involvement of brain hypoperfusion in AD pathogenesis, where cognitive decline 
and dysfunction result from dwindling neuronal energy supply and oxidative stress. In support of 
the vascular hypothesis, evidence suggests measurement of cerebral blood flow (CBF) may be 
a promising indicator of brain hypoperfusion useful for early detection of AD and assessing 
disease progression (Zhang et al., 2017). Consistent with the vascular hypothesis of AD, recent 
results have also demonstrated the potential of CBF as biomarker for preclinical detection of 
AD, as CBF changes present long before amyloid β (Aβ) load or brain atrophy (Hays et al., 
2016). Other studies have discovered the association of CBF with AD stages as well as various 
brain structural and functional imaging quantitative traits (Chen et al., 2011; Musiek et al., 2012; 
Wang et al., 2013; Mattsson et al., 2014; Michels et al., 2016; Bangen et al., 2017). However, 
the molecular mechanisms of CBF changes underlying AD have not been fully understood.  
Given that large variations of CBF have been seen across AD studies, high scientific 
interests have aroused to examine whether they have a genetic basis. Reciprocally, assessing 
the genetic association with CBF might provide a better understanding of molecular 
mechanisms underlying changes of CBF as well as gaining additional insight into complex 
neurodegenerative diseases. To the best of our knowledge, the genetic contributions to CBF is 
an under-explored topic in AD research, except that a few studies examined the APOE effects 
on CBF (Kim et al., 2013b; Hays et al., 2016). Accordingly, in this study, we propose to 
investigate the genetic factors that affect AD through regulating the function of cerebrovascular 
system.  
GWAS have successfully identified a number of loci susceptible for complex neurological 
traits and diseases (Saykin et al., 2015). Recently, a large scale meta-analysis of GWAS 













single nucleotide polymorphisms (SNPs) (Lambert et al., 2013). In addition to APOE, 23 genes 
underlying these 21 significant variants are discovered, most of which are associated with 
inflammation and immune system. For example, there are several genes encoding proteins 
relevant to microglial function and inflammation, including TREM2, CD33, CR1, ABCA7 and 
INPP5D (Malik et al., 2015). Mechanisms of how these genetic factors modulate AD or its 
biomarkers remain to be discovered.  
Based on the VHAD, we hypothesized that some genetic factors impact AD 
pathogenesis via influencing brain hypoperfusion. Thus, this study is designed to improve the 
understanding of mechanisms by which genetic factors impact AD pathogenesis, in this case by 
investigating the role of cerebrovascular functions as an AD endophenotypes. Therefore, in this 
study, we perform a targeted genetic analysis for exploring the genetic effect on CBF measures 
in four brain regions using 24 AD candidate genes (APOE and the other 23 reported AD genes 
mentioned above), to help provide novel insights for better revealing molecular interpretation of 
AD. To evaluate the CBF genetic findings, we further examine non-overlapping samples from 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort regarding their associations with 
the CSF t-tau/Aβ1-42 ratio and FDG-PET glucose metabolism, given that both are established AD 
biomarkers and their abnormalities have been suggested as downstream pathological events 
from initiation of brain hypoperfusion under VHAD (de la Torre, 2018). In addition, to examine 
whether our most significant CBF genetic finding has a direct effect on AD, we further evaluated 
its association with the AD status using the summary statistics from the most recent genome-
wide meta-analysis of AD (Jansen et al., 2019).   
2. Materials and Methods 
2.1. Alzheimer’s Disease Neuroimaging Initiative 
Data used in the preparation of this article were obtained from the ADNI database 
(adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by 
Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test 
whether serial MRI, PET, other biological markers, and clinical and neuropsychological 
assessment can be combined to measure the progression of mild cognitive impairment (MCI) 
and early AD. For up-to-date information, see www.adni-info.org.  
 
2.2. Genome-wide meta-analysis of AD 
A large genome-wide meta-analysis of clinically diagnosed AD and AD-by-proxy was recently 













analysis of the AD status (N = 79,145) using three independent cohorts collected by Alzheimer’s 
disease working group of the Psychiatric Genomics Consortium (PGC-ALZ), the International 
Genomics of Alzheimer’s Project (IGAP), and the Alzheimer’s Disease Sequencing Project 
(ADSP). (2) Phase 2 was a GWAS of the AD-by-proxy status (N = 376,113), using individuals of 
European ancestry from the UK Biobank with parental AD status weighted by age. (3) Phase 3 
was a meta-analysis of the Phase 1 and Phase 2 findings, with totally 455,258 samples (71,880 
cases and 383,378 controls). In this work, we downloaded the summary statistics of the Phase 
3 analysis (available at https://ctg.cncr.nl/software/summary_statistics) to examine whether our 
CBF finding is associated with AD. 
 
2.3. Study participants 
Participants for the current CBF study were limited to those with baseline scans from ADNI in 
the ASL MRI sub study as of May 2012. Full inclusion and exclusion criteria for ADNI are 
described at www.adni-info.org. Detailed quality control (QC) steps for phenotypic and 
genotypic data had been previously reported (Kim et al., 2013a; Wang et al., 2013) and were 
briefly described below. Participants were restricted to non-Hispanic Caucasian to reduce the 
likelihood of population stratification effects in the genetic analysis. A total of 258 non-Hispanic 
Caucasian subjects whose CBF data met all QC criteria were analyzed, including 72 healthy 
control (HC), 16 significant memory concern (SMC), 71 early mild cognitive impairment (EMCI), 
57 late mild cognitive impairment (LMCI) and 42 AD participants. Detailed characteristic 
information and the number of subjects in each sub-group are shown in Table 1. Besides 
participants included in the CBF analysis, non-overlapping samples with various AD 
endophenotypes were studied further for evaluating their associations with the CBF findings. 
See Fig. 1 for detailed information of participant pool selection and study design of this work. 
This study was approved by institutional review boards of all participating institutions and 
written informed consent was obtained from all participants or authorized representatives. 
 
2.4. MRI data acquisition and processing 
Both high-resolution structural MRI data and resting ASL data were downloaded from the ADNI 
website (adni.loni.usc.edu). Image processing used a SPM12 (http://www.fil.ion.ucl.ac.uk/spm) 
based toolbox, ASLtbx (Wang et al., 2008), as described previously (Wang et al., 2013). ASL 
images were processed with the following steps: motion correction (MoCo) (Wang, 2012), 













correction (PVC) (Hu et al., 2010), spatial registration to the Montreal Neurology Institute (MNI) 
standard brain space, and CBF extraction in ROI.  
Mean CBF for four ROIs were studied, including left angular, right angular, left temporal and 
right temporal gyri. The ROIs were selected on the basis FDG-PET literature (Chen et al., 2011; 
Landau et al., 2011; Wang et al., 2013). In particular, meta-region-of-interest (meta-ROI) was 
previously found to be sensitive to AD-related CBF changes (Chen et al., 2011) and originally 
developed for FDG-PET data (Landau et al., 2011), where FDG-PET and ASL showed similar 
patterns of reduction in brain regions covered by these ROIs. A follow-up study also explored 
these ROIs using the same parcellation template and demonstrated the sensitivity of CBF on 
these ROIs for early AD. See Supplementary Methods for detailed MRI data acquisition, 
processing and analysis. 
 A total of 299 subjects were included in the ASL-MRI processing. To restrict the present 
analysis to non-Hispanic Caucasians, 258 subjects were identified based on population 
stratification information from genotyping data processing. Considering the relatively small 
number of samples for the genetic analysis, we performed further quality control to reduce the 
potential influence of extreme outliers. Mean and standard deviation of CBF measures for each 
ROI were calculated, blind to diagnostic information. Subjects who had at least one value 
greater or smaller than six standard deviations from the mean value of each of four CBF 
variables were detected as outliers. No subjects were identified as outliers and removed from 
this criterion. Finally, 258 subjects with four lists of quality controlled CBF measures were 
included (Fig. 1). 
 
2.5. CSF Biomarkers 
The total tau (t-tau) and amyloid-β 1-42 peptide (Aβ1-42) measured in the baseline CSF samples 
were obtained from the ADNI database (adni.loni.usc.edu). Sample acquisition and quality 
control of CSF were performed as described previously (Shaw et al., 2009). The t-tau/Aβ1-42 
ratio was calculated for 919 subjects who were non-Hispanic Caucasians as well as not 
included in the CBF analysis. Further quality control was performed to reduce the potential 
influence of extreme outliers on statistical results. Mean and standard deviation of t-tau/Aβ1-42 
ratio were calculated, while subjects with greater or smaller than six standard deviation from the 
mean value were regarded as outliers. 13 subjects were removed, where 12 subjects had 
missing t-tau/Aβ1-42 measures, and 1 subject had extremely high t-tau/Aβ1-42 ratio. Finally, 906 














2.6. FDG-PET data acquisition and processing 
Given the certain agreement of CBF changes and cerebral metabolic rate of glucose on some 
brain regions (Chen et al., 2011; Musiek et al., 2012), considerable variability on some other 
regions was also observed. With this observation, we also examined the relationship between 
the CBF genetic findings and glucose metabolism measurements. Preprocessed FDG-PET 
scans were downloaded from the ADNI website (adni.loni.usc.edu) and processed as previously 
described in (Risacher et al., 2015). FDG-PET scans were then aligned to the corresponding 
MRI scans and normalized to the MNI space as 2 × 2 × 2 mm3 voxels. ROI-level glucose 
metabolism measurements were further extracted based on the MarsBaR AAL atlas for 735 
subjects who were not included in the CBF genetic analysis. Here we focused only on the left 
angular region (L-AG) on which the CBF genetic association was identified. Subjects were 
treated as outliers and excluded if their left angular FDG-PET measures were greater or smaller 
than six standard deviations from the mean value. No subjects were removed under this 
criterion, and finally 735 subjects with quality-controlled left angular FDG-PET measured 
glucose metabolism were analyzed (Fig. 1). 
 
2.7. Genotyping data 
Genotyping data were obtained from the ADNI database (adni.loni.usc.edu). They were quality-
controlled, imputed and combined as described in (Kim et al., 2013a). Briefly, genotyping was 
performed on all ADNI participants following manufacturer’s protocol using blood genomic DNA 
samples and Illumina GWAS arrays (610-Quad, OmniExpress, or HumanOmni2.5-4v1) (Saykin 
et al., 2010). Quality control was performed in PLINK v1.90 (Purcell et al., 2007) using the 
following criteria: 1) call rate per marker ≥ 95%, 2) minor allele frequency (MAF) ≥ 5%, 3) Hardy 
Weinberg Equilibrium (HWE) test P ≥ 1.0E-6, and 4) call rate per participant ≥ 95%. Significant 
relatedness pairs with PI_HAT > 0.45 were identified and thereafter one individual from each 
pair was randomly excluded (similar to the approach applied in (Ramanan et al., 2015)). 
Participants were then checked for gender and identity-by-descent before imputation to identify 
genotyping or coding error and to avoid the potential confounding effect due to the gender 
ambiguity or consanguinity such as sibling pairs. To restrict the studied participants to non-
Hispanic Caucasians, we further performed population stratification using 988 subjects with 
known ancestry information from HapMap3 as reference data. We merged the ADNI and 
HapMap3 samples, and performed multidimensional scaling analysis using PLINK v1.90 with 
identity-by-state (IBS) pairwise distance matrix on the merged data to clustering samples in the 













Caucasians if: 1) they were clustered with HapMap3 CEU or TSI subjects as well as had self-
reported race/ethnicity as “non-Hispanic/white”, or 2) they were not clustered with any HapMap3 
subjects while had self-reported race/ethnicity as “non-Hispanic/white”. Haplotype patterns from 
the 1,000 Genomes Project reference panel were then applied to impute the SNPs that were not 
directly genotyped from arrays. 5,574,300 SNPs were obtained for all subjects involved in this 
work (see Supplementary Methods for more details about genotyping data imputation). To 
appropriately control for population stratification, we used PLINK v1.90 to generate the top four 
principal components to be included as covariates in our genetic association analyses. 
 A list of 24 AD candidate genes from the large scale meta-analysis (Lambert et al., 
2013) were analyzed. Given that the Genome Reference Consortium Human build 37 
(GRCh37) was used as reference genome for genotyping, gene annotation from GRCh37 was 
employed to extract SNPs located within each AD gene. Two genes (HLA-DRB1 and HLA-
DRB5) had no SNPs available in our imputed genotyping data. In total, 4,033 SNPs were 
included in the genetic association analysis. Detailed information of these genes is available in 
Supplementary Table 1.  
 
2.8. Statistical analysis 
Targeted genetic association analysis of CBF on each ROI was tested using linear regression 
under an additive genetic model in PLINK v1.90 (Purcell et al., 2007). Age, gender APOE ɛ4 
status and the top four principal components from population stratification analysis were 
included as covariates. Post-hoc analysis used Bonferroni correction for adjusting both the 
number of SNPs and the number of quantitative traits. Regional genetic association plot was 
generated using LocusZoom (Pruim et al., 2011). Gene-based association analysis was 
employed to gain comprehensive statistical evidence of genetic findings. We used GATES (Li et 
al., 2011) to calculate a gene-level summary P-value for each gene by taking into account gene 
size, linkage disequilibrium (LD) and constituent SNP level P-values.  
 Phenotypic variance explained by an identified genetic variant was evaluated using the 
linear regression after removing effects from age, gender, APOE ɛ4 status and the top four 
principal components from population stratification analysis. Both linear regression coefficient P 
value and Cohen’s d statistic were used to illustrate the significance and effect size of identified 
variant, to facilitate the comparison among different genotyping groups. 
 The additive effects of the identified genetic variants from above association analysis 
were also assessed at each voxel using SPM12 under one-way ANOVA test with age, gender, 













covariates. The statistical analysis results were assessed at P < 0.001 with no correction. The 
genetic effects were mapped onto the brain via voxel-based analysis.  
 Genetic findings from the CBF analysis were further investigated in non-overlapping 
samples regarding their associations with the CSF t-tau/Aβ1-42 ratio and left angular FDG-PET 
glucose metabolism. For both association tests, linear regression models were used. In 
particular, we applied additive genetic models implemented in PLINK v1.90 (Purcell et al., 
2007), with age, gender, APOE ɛ4 status and the top four principal components from population 
stratification analysis as covariates.  
3.  Results 
3.1. Participant characteristics 
A total of 258 ADNI subjects were studied in the CBF genetic association analysis (see Table 1 
for their characteristics). There were 25 subjects with missing CBF measures in one or more 
ROIs (2 subjects for left angular region, 2 subjects for right angular region, 12 subjects for left 
temporal region, and 11 subjects for right temporal region). Using one-way ANOVA or Chi-
squared test, significant differences among diagnostic groups were observed for MMSE scores 
(P = 2.20E-16) and APOE ɛ4 status (present of APOE ɛ4 or not; P = 0.0015), while not 
observed for age, gender or any CBF measure.  
 
3.2. Targeted genetic association of CBF 
To identify the genetic predictor of CBF, we performed a targeted genetic association analysis 
(N = 258) of CBF measurements in four brain ROIs using AD risk genes and controlling for age, 
gender, APOE ɛ4 status and the top four principal components from population stratification 
analysis. A total of 4,033 SNPs located in AD candidate genes were studied.  
 Genetic association analysis identified one significant association between rs61068452 
with L-AG CBF (P = 1.48E-7; corrected P = 2.39E-3) after correcting for the number of variants 
and the number of phenotypes using the Bonferroni method. The minor allele G of rs61068452 
(rs61068452-G) was associated with higher CBF in L-AG compared to its major allele A (Fig. 
2B). It explained an additional 9.57% of the phenotypic variance of L-AG CBF that exhibited the 
protective effect on AD. Significant difference of L-AG CBF existed between AA and AG groups 
(P = 1.43E-4), between AA and GG groups (P = 1.53E-5), and between groups AG and GG (P 
= 0.24). The recessive homozygote showed higher Cohen’s d statistics when compared with 
other two groups (i.e., Cohen’s d = 2.52 between AA and GG groups, Cohen’s d = 1.45 between 













rs61068452-G was associated with increased L-AG CBF in all diagnostic groups 
(Supplementary Fig. 2A). 
 The SNP rs61068452 resides in an intron of INPP5D, a reported AD candidate gene 
involved in inflammatory responses (Fig. 2A). Rs35349669, another SNP located within 
INPP5D, has been reported as risk AD variant in several studies (Lambert et al., 2013; Ruiz et 
al., 2014; Farfel et al., 2016; Jing et al., 2016). In our CBF genetic studies, no significant 
association of rs35349669 was observed with CBF for any region (P > 0.05) based on the 
studied samples.  
 Due to the possible opposite effects of our reported variant rs61068452 and previously 
reported variant rs35349669, we assessed their relationship. Correlation between these two 
SNPs was -0.22, according to the genotyping data from the studied 258 subjects. There existed 
no linkage disequilibrium between these two SNPs, with r2 = 0.046 computed from the 
genotyping data of the studied 258 samples (see Supplementary Fig. 1).  
 We further investigated the effect of the APOE ɛ4 allele (rs429358) due to its well-known 
association with AD diagnosis. We did not observe significant association of rs429358 with CBF 
in four ROIs in the studied sample. Fig. 3 illustrated the additive effect of INPP5D rs61068452 
on CBF under voxel-wise analysis, adjusted for age, gender, APOE ɛ4 status and the top four 
principal components from the population stratification analysis. The minor allele (G) of 
rs61068452 was associated with higher CBF, with significant clusters for this effect observed 
primarily in L-AG.  
 
3.3. Gene-based association analysis of CBF 
Complementary analysis was employed to test the gene-based association with CBF measures 
in L-AG. We assessed the gene-based association with L-AG CBF using 4,033 SNP statistics in 
GATES (Li et al., 2011). Two genes displayed significant associations with L-AG CBF including 
INPP5D (P = 1.5E-3) and CD2AP (CD2 associated protein; P = 2.0E-2), after Bonferroni 
correction for the number of genes (Supplementary Table 2).  
 
3.4. Association of INPP5D rs61068452 with CSF t-tau/Aβ1-42 ratio 
Given the effect of rs61068452 with CBF measures in brain region, we hypothesized that 
INPP5D rs61068452 would also be associated with CBF related AD biomarkers. We tested the 
hypothesis through assessing the association of rs61068452 with CSF t-tau/Aβ1-42 ratio in 906 
subjects (Supplementary Table 3) from ADNI who were not included in the CBF genetic 













tau/Aβ1-42 ratio (P = 0.014; Fig. 4A) under linear regression with age, gender, APOE ɛ4 status 
and the top four principal components as covariates. We also tested the relevance of the 
previously reported INPP5D SNP rs35349669, and identified its association with higher CSF t-
tau/Aβ1-42 ratio (P = 0.028). We observed that the minor allele (G) of rs61068452 was 
associated with decreased CSF t-tau/Aβ1-42 ratio across all diagnostic groups (Supplementary 
Fig. 2B). 
 
3.5. Association of INPP5D rs61068452 with FDG-PET  
Recent studies have reported different relationships between ASL MRI and FDG-PET in 
different brain regions, including the similar abnormalities in some regions (Chen et al., 2011; 
Musiek et al., 2012) and decoupling between perfusion and metabolism in other brain regions 
(Cha et al., 2013). We first explored the association of rs61068452 with glucose metabolism of 
left angular region measured by FDG-PET in 735 subjects from ADNI who were not included in 
our previous CBF analysis (Supplementary Table 4). There existed no significant association 
between rs61068452 and left angular glucose metabolic rate (P = 0.111, Fig. 4B) under linear 
regression with age, gender, APOE ɛ4 status and the top four principal components as 
covariates; while the minor allele (G) of rs61068452 showed a trend of association with 
increased glucose metabolic rate in L-AG for all diagnostic groups except healthy controls 
(Supplementary Fig. 2C). 
 
3.6. Association of INPP5D rs61068452 with AD 
To examine whether the genetic finding from our CBF analysis is directly associated with the AD 
status, we leveraged the valuable results available from the most recent large-scale genome-
wide meta-analysis of AD (Jansen et al., 2019). According to the summary statistics of the 
Phase 3 analysis in this study, rs61068452 exhibited a significant association with AD (P = 
1.54E-04; N = 456,488). The corresponding effect size is -0.0164, indicating a protective role of 
rs61068452-G in AD. This aligns well with our CSF finding. 
4. Discussion 
Targeted genetic analysis of AD candidate genes discovered a novel association between the 
SNP rs61068452 in INPP5D and a regional CBF measure in 258 ADNI subjects. To the best of 
our knowledge, this is among the first genetic association analyses of CBF measured by ASL 
perfusion MRI in AD-related studies. We identify that INPP5D rs61068452-G is associated with 













validated in a large meta-analysis of AD (N = 456,488), as well as shown in non-overlapping 
samples from ADNI, where it is associated with AD CSF biomarker (N = 906) and left angular 
glucose metabolism measured by FDG-PET (N = 735).  
INPP5D is a known negative regulator of inflammation, and has been reported to be 
associated with late-onset AD in a large meta-analysis of GWAS case control study (Lambert et 
al., 2013; Yoshino et al., 2017). It has been further investigated and reviewed for its function in a 
number of pathways including microglial activation, neuroinflammation, and immune response 
(Malik et al., 2015; López González et al., 2016; Yoshino et al., 2017). INPP5D mRNA analysis 
has revealed significantly higher expression in AD than in healthy control subjects, and 
suggested its involving role in microglial function via DAP12 (DNAX-activating protein of 12kD) 
(Yoshino et al., 2017). 
 INPP5D encodes a protein called SHIP1 (phosphatidylinositol-3,4,5-trisphosphate-5-
phosphatase 1). Our reported SNP rs61068452 is an intronic variant of INPP5D, locating nearby 
the INPP5D transcription starting site, which is related to the regulation of SHIP1 by modulating 
the SH2 (Src Homology 2) domain. Therefore, one possible role which rs61068452 could play is 
to regulate the production of SHIP1. Another previously reported AD risk variant, INPP5D SNP 
rs35349669, is not associated with CBF phenotypes in the studied samples. However, it is 
significantly associated with CSF t-tau/Aβ1-42 ratio in the subsequent biomarker analysis with 
opposite effect direction compared to rs61068452. There are multiple transcription factors of 
INPP5D for modulating the production of SHIP1. The SNPs rs61068452 and rs35349669 are 
located in different introns and independent from each other according to their linkage 
disequilibrium value. In addition, rs61068452 resides in regions that are related to the SH2-
domain, while rs35349669 resides in regions regulating endonuclease. Thus, it warrants further 
investigation to examine how the molecular functions of rs61068452 and rs35349669 differ.  
 Recent studies of mouse model also indicate the important role of INPP5D in AD, 
especially in microglia. In particular, a recent work has demonstrated the conservative of 
transcriptomic between human and mouse microglia, and illustrated the higher expression level 
of INPP5D in them (Gosselin et al., 2017). In another study of AD immune basis, overlap of AD 
associated variants within INPP5D with increasing enhancer has been identified in AD mouse 
model, as well as overlap with immune enhancer in human CD14+ primary cells (Gjoneska et 
al., 2015). Our reported variant, INPP5D rs61068452, overlaps with this enhancer region and is 
only ~10K bp from these variants. The transcription site nearby which rs61068452 is located 
encodes SH2 domain. Therefore, this may indicate a possible function of rs61068452 for 













evidences for using mouse model to gain a better understanding of human neurodegenerative 
diseases. 
In addition to INPP5D, our gene-based association analysis also discovered CD2AP 
(CD2 associated protein) associated with left angular CBF. Recent studies have identified 
interactions between INPP5D and several other AD candidates and studied their associations 
with AD pathogenesis. In particular, SHIP1, protein encoded by INPP5D, complexes with 
CD2AP to inhibit the ubiquitination of pro-inflammatory proteins Syk (spleen tyrosine kinase) 
and FcγRIIa (CD32) (Bao et al., 2012). SHIP1 has also been investigated for inhibiting TREM2 
(triggering receptor expressed on myeloid cell 2) signaling by binding to DAP12 and preventing 
the recruitment of PI3K (phosphatidylinositol 3-kinase) to DAP12 (Peng et al., 2010; Malik et al., 
2015; Yoshino et al., 2017). Functional interactions among these genes may help supply 
meaningful information for understanding the underlying molecular mechanism. 
Pathologically, interactions between CBF and neuroinflammation and their effects on 
neurodegenerative diseases have been explored. CBF is regulated by activations of neurons 
and glial cells, including microglia which are the main resident immune cells in brain. Increased 
activation of microglia has been shown linked to neurodegenerative diseases including AD. 
Relationships between microglia and brain blood flow have also been largely studied (Attwell et 
al., 2010; Szalay et al., 2016), further suggesting their involvements in AD.  
 In this work, we discover that rs61068452-G is associated with higher CBF in L-AG. 
Given that hypoperfusion of L-AG is an established imaging biomarker of AD and early AD (Liu 
et al., 2015; Suwa et al., 2015), increased L-AG CBF in the G-carriers of rs61068452 may 
represent a protective role in AD neuropathogenesis. It is further validated in a large meta-
analysis of AD for the protective effect of G-carriers of rs61068452.  
 According to the discovery of rs61068452 from targeted genetic analysis, we test its 
association with other AD endophenotypes including CSF t-tau/Aβ1-42 ratio and glucose 
metabolism measured by FDG-PET. The minor allele (G) of rs61068452 is significantly 
associated with lower SF t-tau/Aβ1-42 ratio and shows a trend towards higher glucose 
metabolic rate in left angular region. Both CSF and FDG-PET hold promise as early markers for 
preclinical of AD, while CSF biomarkers have been thought to be a type of “AD signature”, due 
to their predictive power for accurate and early diagnosis of AD (Blennow et al., 2015; De Deyn, 
2015; Skillbäck et al., 2015). Therefore, these findings further suggest the protective effect of 
the G allele of rs61068452 for AD. 
In conclusion, we have revealed a novel association between the minor allele (G) of 













finding to AD endophenotypes including CSF t-tau/Aβ1-42 ratio. This study has focused on AD 
candidate genes, given the modest sample size in a genetic association study. Future 
investigation is warranted to conduct a replication study with larger sample(s) from independent 
cohorts. Another future direction is to perform the longitudinal CBF analysis for characterizing 
disease progression. The molecular mechanism of identified INPP5D rs61068452 warrants 
further investigation, including how it modulates SHIP1 transcription, interacts with other AD 
genes like TREM2, CD2AP, and affects the microglia activation and inflammation. Another 
future topic is to examine the biological role of INPP5D rs61068452 in vascular system, given 
the evolving of vascular system on CBF controlling and brain functions. In addition, AD animal 
models merit further investigation and may provide helpful information for filling the gap between 
neurodegenerative disease mechanisms and genetic risk and protective factors. 
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Table 1. Participant characteristics in CBF genetic association analysis 
Diagnosis HC SMC EMCI LMCI AD P value 
Number 72 16 71 57 42 - 
Gender (M/F) 35/37 7/9 45/26 27/30 21/21 0.25 
Age (mean±sd) 75.03±7.42 73.56±6.87 74.01±7.46 73.88±7.66 73.67±7.74 0.83 
APOE ɛ4 present 30.99% 37.50% 40.85% 54.39% 69.05% 1.5E-03 
MMSE  
(mean±sd) 29.04±1.16 29.40±0.99 28.43±1.55 27.23±2.02 23.85±2.96 2.2E-16 
Left angular  
CBF (mean±sd) 50.29±23.96 51.77±22.48 50.41±20.48 51.47±24.42 43.14±21.11 0.39 
Right angular  
CBF (mean±sd) 52.90±22.59 46.69±16.93 49.25±20.66 57.82±27.14 50.99±25.75 0.28 
Left temporal  
CBF (mean±sd) 44.76±19.31 46.06±15.51 44.34±24.28 43.56±21.65 37.45±21.07 0.46 
Right temporal  
CBF (mean±sd) 46.36±23.09 34.37±17.91 40.90±18.80 44.77±23.31 37.23±19.41 0.09 
CBF-cerebral blood flow, AD-Alzheimer’s disease, HC-healthy control, SMC-significant memory 
concern, EMCI-early mild cognitive impairment, LMCI-late mild cognitive impairment. P values 
were assessed due to significant differences among diagnosis groups, and were computed 
















Figure 1. Flowchart of participant selection and study design.  
Figure 2. Association and effect of INPP5D rs61068452 on left angular CBF. (A) All SNPs 
within INPP5D are plotted based on their genetic association statistics -log10 P values. NCBI 
build 37 genomic position and recombination rates are calculated from the 1,000 Genome 
Project reference data. The color scale of r2 values is used to label SNPs based on their degree 
of linkage disequilibrium with rs61068452. Genes in the region are labeled with arrows denoting 
5’- to -3’ orientation. (B) Mean left angular CBF measures and standard errors are plotted 
against rs61068452 genotype groups (AA, AG, and GG). P value indicates the association 
significance of rs61068452 with left angular CBF. P values are calculated from linear regression 
with age, gender, APOE ɛ4 status and the top four principal components from population 
stratification analysis as covariates. Cohen’s d indicates the effect size of minor allele G (one 
copy or two copies) of rs61068452 on left angular CBF, after being adjusted for age, gender, 
APOE ɛ4 status and the top four principal components from population stratification analysis. 
Presence of minor allele G of rs61068452 suggests an additive effect of increasing left angular 
CBF and this SNP accounts for 9.57% of the phenotypic variance.  
Figure 3. Effect of INPP5D rs61068452 on cerebral blood flow. Selected sectional slices 
(top) and surface renderings (bottom) represent the voxel-wise analysis of the additive effect of 
rs61068452-G on CBF. The color scale indicates significance (-log10 P value) of association 
between rs61068452 and CBF measure (i.e., GG > AG > AA). All comparisons are displayed at 
a voxel-wise threshold of uncorrected P < 0.001 with minimum cluster size of 800 voxels 
(approximately responding to a cluster-wise threshold of FDR-corrected P < 0.05). The most 
significant clusters are present in the left angular gyrus.  
Figure 4. Association of INPP5D rs61068452 on CSF t-tau/Aβ1-42 ratio and FDG 
metabolism. (A) Mean CSF t-tau/Aβ1-42 ratio with standard errors are plotted against the 
rs61068452 genotype groups (i.e., AA and AG, no GG participants in this sample). P value and 
Cohen’s d respectively indicates the significance and effect size of the association between 
rs60168452 and CSF t-tau/Aβ1-42 ratio, with age, gender, APOE ɛ4 status and the top four 
principal components from population stratification analysis as covariates. Presence of minor 
allele (G) of rs61068452 is associated with decreasing CSF t-tau/Aβ1-42 ratio. (B) Mean left 
angular FDG-PET glucose metabolism with standard errors are plotted against the rs61068452 






























4033 SNPs of 24 AD gene




226 in CBF analysis; 93 not
non-Hispanic Caucasian; 12
had missing data; 1 failed
outlier detection.
CSF: 906 participants




FDG PET: 735 participants
(170 HC, 71 SMC, 210 EMCI, 136
LMCI, 148 AD)
254 participants excluded:
included in CBF analysis.
CBF: 299 participants
CBF: 258 participants
(72 HC, 16 SMC, 71 EMCI, 57 LMCI, 42 AD)
41 participants excluded: 37 
participants are not non-Hispanic 
Caucasian; 4 participants had no 
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Cohen’s d = 2.52
P = 1.43E-04***





































































































Targeted genetic analysis of cerebral blood flow imaging phenotypes implicates the INPP5D gene 
Highlights 
• We performed a targeted genetic study of cerebral blood flow (CBF) phenotypes captured by arterial 
spin labeling (ASL) perfusion magnetic resonance imaging (pMRI). 
• We discovered a novel locus in INPP5D (rs61068452) significantly associated with the CBF measure in 
the left angular gyrus (L-AG). 
• The identified genetic variation was also associated with several AD biomarkers. 
• This work is among the first genetic association studies of CBF in AD, and our finding has the potential 
to help understand AD molecular mechanism. 
 
